Clinical Trials | August 26, 2024
Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Subscribe To Our Newsletter & Stay Updated
